We develop and manufacture high quality, high value immunohematology (blood banking) products which are sold to hospitals and blood banks around the world. We also offer contract services to the bioscience industry and currently manufacture products for major global players in the Life Sciences sectors.

Quotient offers more than 30 years of research, development and manufacturing of transfusion diagnostics products that have traditionally have been sold worldwide either directly or by other major transfusion companies.

Quotient currently operates from three sites in Edinburgh, UK and offices in Switzerland and the US.

Where we’ve come from

The history of Quotient begins with the Scottish National Blood Transfusion Service (SNBTS), which has manufactured blood typing reagents since the early 1940’s.

• 1990
Diagnostics manufacture was centralised in Edinburgh with formation of the National Reagents Unit (NRU)
• 1998
SNBTS created ‘Diagnostics Scotland’ by merging the NRU and the Scottish Antibody Production Unit (SAPU)
• 2005
Diagnostics Scotland rebranded as ‘Alba Bioscience’
• 2007
Privatisation of Alba Bioscience – acquired by Quotient Bioscience Group
• 2008
Quotient Biodiagnostics Inc established in US
• 2011
Control transferred to Quotient Biodiagnostics Group
• 2013
Alba Bioscience rebranded as ‘Quotient’
• 2014
Quotient Suisse SA established in Eysins. Flotation on US Stock Market (NASDAQ)


Our Products

The majority of our products are used in the field of Immunohaematology and are used to ensure, as far as possible, the safe transfusion of blood and blood products. To this end our products are subjected to very high quality standards as the result of any error in blood typing could have very serious implications for the patient.

Our products and services include those used:

  • To determine the blood group of blood donations and patients
  • To work as a control in order to validate test results and equipment
  • For the detection and identification of unexpected antibodies in blood
  • For the assessment of staff competence in the transfusion laboratory

We also produce niche products used for more in-depth testing, for example in complex cases where samples require further investigation to identify irregular blood groups or blood group antibodies.

Transforming Transfusion Diagnostics

The immediate future focus for Quotient is the development of our presence in the US marketplace. Since 2009, Quotient has built a direct commercial infrastructure in North America and the United Kingdom, while we continue to serve the OEM market. Quotient has over 200 products it manufactures and sells worldwide in over 30 countries.

The next phase for Quotient is its development project, MosaiQ™. This is an automated, multiplexed diagnostic platform for donor and patient blood testing utilizing a protein microarray based on long established serologic reactions.

The goal is to create a single assay capable of incorporating antigen typing, antibody identification and viral screening. The MosaiQ™ project would consolidate what in today’s environment would require a number of automated platforms and manual testing into a single platform and single assay.

Return to Quotient Careers